CD86 and carcinoma: In BMDCs, we found upregulation of the costimulatory molecule CD86 upon interaction with necroptotic MOC1 cells which was dependent on active RIPK3 and MLKL in carcinoma cells and was blocked by necrostatin-1 (figure 4D).